<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482765</url>
  </required_header>
  <id_info>
    <org_study_id>UAS/170901/PB/IBS</org_study_id>
    <nct_id>NCT03482765</nct_id>
  </id_info>
  <brief_title>A Study of Probiotics in IBS Subjects</brief_title>
  <official_title>A Double-blind Randomized, Placebo-controlled, Parallel Group Study of the Efficacy and Safety of Probiotics (UABla-12™ and DDS®-1) on Digestive Health in IBS Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the current study, the primary outcome is to evaluate the effect of IP on abdominal pain.&#xD;
&#xD;
      The secondary outcome is to assess the effect of IP on IBS-Symptom Severity, IBS-related&#xD;
      quality of life, stool form and consistency and on mental status.&#xD;
&#xD;
      Thus providing an effective objective in improving the gut health and symptomatic relief in&#xD;
      IBS patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to determine the effect of probiotics, as the investigational products (IPs)&#xD;
      in subjects satisfying the Rome IV criteria for IBS. Three hundred and sixty six subjects&#xD;
      between 18 to 70 years of age and with a positive diagnosis of Rome IV IBS criteria (IBS-C,&#xD;
      D, M and U types) and moderate to severe abdominal pain intensity will be recruited in a&#xD;
      multi-center, double-blind, parallel group, placebo-controlled randomized trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2018</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">March 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Apart from the participant and Investigator, the study team is also blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in abdominal pain severity</measure>
    <time_frame>42 days</time_frame>
    <description>The change at Day 42 will be assessed by subject dairy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in abdominal pain severity</measure>
    <time_frame>Day 21</time_frame>
    <description>The change at Day 21 will be assessed by subject dairy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IBS symptoms</measure>
    <time_frame>Day 42</time_frame>
    <description>The change at Day 42 will be compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stool consistency</measure>
    <time_frame>Day 42</time_frame>
    <description>The change at Day 42 will be compared to baseline by specific questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Day 42</time_frame>
    <description>The change at Day 42 will be compared to baseline by specific questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daily number of stools</measure>
    <time_frame>Day 42</time_frame>
    <description>The change at Day 42 will be compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">336</enrollment>
  <condition>IBS</condition>
  <arm_group>
    <arm_group_label>Probiotic 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic 1: A dietary probiotic supplement which contains Bifidobacterium lactis. Dose: &gt; 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic 2: A dietary probiotic supplement which contains Lactobacillus acidophilus. Dose: &gt; 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Placebo contains MCC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic 1</intervention_name>
    <description>The product under investigation is a unique probiotic.</description>
    <arm_group_label>Probiotic 1</arm_group_label>
    <other_name>Bifidobacterium lactis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic 2</intervention_name>
    <description>The product under investigation is a unique probiotic.</description>
    <arm_group_label>Probiotic 2</arm_group_label>
    <other_name>Lactobacillus acidophilus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Microcrystalline Cellulose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Literate (as defined by the basic capability to read and understand in the languages&#xD;
             approved for the study), male and female subjects in age range of 18-70 years.&#xD;
&#xD;
          -  Presence of Rome IV diagnostic criteria for IBS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anemic subjects with Hb &lt; 10 g/dl.&#xD;
&#xD;
          -  Subjects with organic disease (to be ruled out by physician based on prior history and&#xD;
             physical examination).&#xD;
&#xD;
          -  Subjects with a history of surgical resection of the stomach, small intestine or large&#xD;
             intestine.&#xD;
&#xD;
          -  Subjects with a history of or complications from inflammatory bowel disease (Crohn's&#xD;
             disease or ulcerative colitis) and ischemic colitis.&#xD;
&#xD;
          -  Subjects with complications from infectious enteritis, hyperthyroidism or&#xD;
             hypothyroidism.&#xD;
&#xD;
          -  Subjects with a history of any diet-based intolerance (gluten or lactose intolerance).&#xD;
&#xD;
          -  Subjects with a history of drug or alcohol abuse within the past 6 months.&#xD;
&#xD;
          -  Subjects with a history of or complications from malignant tumors.&#xD;
&#xD;
          -  Subjects with severe depression or an anxiety disorder, which could potentially affect&#xD;
             the efficacy evaluation (as determined by the qualified investigator).&#xD;
&#xD;
          -  Subjects with uncontrolled hypertension (≥140/90 mm Hg).&#xD;
&#xD;
          -  Subjects with complications from serious cardiovascular diseases, respiratory&#xD;
             diseases, endocrinological and gynecological disorder, renal diseases, hepatic&#xD;
             diseases, gastrointestinal diseases (excluding IBS), blood diseases or neurological or&#xD;
             psychiatric diseases.&#xD;
&#xD;
          -  Subjects who are pregnant, breastfeeding or planning on becoming pregnant throughout&#xD;
             the course of the study.&#xD;
&#xD;
          -  Subjects with a history of dysmenorrhea.&#xD;
&#xD;
          -  Subjects with any unstable medical conditions.&#xD;
&#xD;
          -  Subjects with uncontrolled Type II diabetes mellitus.&#xD;
&#xD;
          -  Subjects with a history of or current diagnosis of any cancer (except for successfully&#xD;
             treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects&#xD;
             with cancer in full remission more than 5 years after diagnosis are acceptable.&#xD;
&#xD;
          -  Subjects who are immuno-compromised (HIV positive, on anti-rejection medication,&#xD;
             rheumatoid arthritis).&#xD;
&#xD;
          -  Subjects with any medical condition or a history of abdominal surgery that is deemed&#xD;
             exclusionary by the qualified investigator.&#xD;
&#xD;
          -  Subjects with an active eating disorder.&#xD;
&#xD;
          -  Subjects who have used an over-the-counter or prescription laxative medication or any&#xD;
             other herbal agents affecting GI motility within 2 weeks prior to screening.&#xD;
&#xD;
          -  Subjects who have used probiotic or fiber supplements (or probiotic/fiber enriched&#xD;
             foods) or an antibiotic within 4 weeks prior to screening.&#xD;
&#xD;
          -  Subjects who have used IBS specific treatments within 4 weeks prior to screening.&#xD;
&#xD;
          -  Subjects who currently consume greater than 2 standard alcoholic drinks per day from&#xD;
             past 3 months.&#xD;
&#xD;
          -  Subjects who smoke ≥ 1 cigarette per day. Occasional (Non-daily) smokers will be&#xD;
             allowed.&#xD;
&#xD;
          -  Subjects who have participated in a clinical research trial within 30 days prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Subjects with an allergy or sensitivity to the probiotic products.&#xD;
&#xD;
          -  Subjects who are cognitively impaired and/or who are unable to give an informed&#xD;
             consent.&#xD;
&#xD;
          -  Subjects who have abnormal laboratory results or any other medical or psychological&#xD;
             condition which, in the opinion of the qualified investigator, may adversely affect&#xD;
             the subjects' ability to complete the study or its measures or which may pose&#xD;
             significant risk to the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalini Srivastava, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Vedic Lifesciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Apex Gastro Clinic</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrocare &amp; Liver Clinic</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Gut Clinic</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vazifdar Clinic</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400055</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stress Test Clinic</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400059</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shantaee Nursing Home</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400067</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Sanjeev Khanna's Clinic</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400069</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ameeta Nursing home</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400071</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancelot Kidney and GI Center</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kshirsagar Nursing Home</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400602</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samarth Clinic</name>
      <address>
        <city>Navi Mumbai</city>
        <state>Maharashtra</state>
        <zip>400703</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sampada Hospital</name>
      <address>
        <city>Thāne</city>
        <state>Maharashtra</state>
        <zip>400601</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

